Monopar Therapeutics Inc.
MNPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.10 | -1.05 | -0.85 |
| FCF Yield | -7.68% | -31.86% | -4.80% | -3.66% |
| EV / EBITDA | -2.32 | -1.97 | -13.53 | -19.71 |
| Quality | ||||
| ROIC | -29.37% | -158.05% | -104.35% | -48.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.94 | 0.69 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 18.50% | -8.71% | 1.21% | -56.95% |
| Safety | ||||
| Net Debt / EBITDA | 2.83 | 0.82 | 0.78 | 2.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |